Synthesis of imidazo[1,5,4-de]quinoxalin-9-ones, benzimidazole analogues of pyrroloiminoquinone marine natural products

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 2, 2005, Pages 387-395

  LaBarbera, Daniel V ^a   Skibo, Edward B ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Benzimidazole; Imidazoquinoxalinones; Pyrroloiminoquinone

Indexed keywords

7 ACETAMIDO 2,8 DIMETHYL 4,5 DIHYDROIMIDAZO[1,5,4 DE]QUINOXALIN 9 ONE; 8 AMINO 2 METHYL 4,5 DIHYDROIMIDAZO[1,5,4 DE]QUINOXALIN 9 ONE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; NATURAL PRODUCT; PROTEIN TYROSINE KINASE; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HOLLOW FIBER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DNA TOPOISOMERASES, TYPE II; HUMANS; IMIDAZOLES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PORIFERA; QUINOXALINES;

EID: 10444221780     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.10.016     Document Type: Article

References (20)

1. B.R. Copp, C.M. Ireland, and L.R. Barrows Wakayin: a novel cytotoxic pyrroloiminoquinone alkaloid from the ascidian Clavelina species J. Org. Chem. 56 1991 4596 4597
2. L.R. Barrows, D.C. Radisky, B.R. Copp, D.S. Swaffar, R.A. Kramer, R.L. Warters, and C.M. Ireland Makaluvamines, marine natural products, are active anti-cancer agents and DNA topo II inhibitors Anti-Cancer Drug Des. 8 1993 333 347
3. D.C. Radisky, E.S. Radisky, L.R. Barrows, B.R. Copp, R.A. Kramer, and C.M. Ireland Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from Fijian sponges of the genus Zyzzya J. Am. Chem. Soc. 115 1993 1632 1638
4. I. Islam, and E.B. Skibo Synthesis and physical studies of azamitosene and iminoazamitosene reductive alkylating agents. Iminoquinone hydrolytic stability, syn/anti isomerization, and electrochemistry J. Org. Chem. 55 1990 3195 3205
5. W.G. Schulz, E. Islam, and E.B. Skibo Pyrrolo[1,2-a]benzimidazole-based quinones and iminoquinones. The role of the 3-substituent on cytotoxicity J. Med. Chem. 38 1995 109 118
6. W.G. Schulz, and E.B. Skibo Inhibitors of topoisomerase II based on the benzodiimidazole and dipyrroloimidazobenzimidazole ring systems: controlling DT-diaphorase reductive inactivation with steric bulk J. Med. Chem. 43 2000 629 638
7. E.B. Skibo Pyrrolobenzimidazoles in cancer treatment Expert Opin. Ther. Pat. 8 1998 673 701
8. E.B. Skibo The discovery of the pyrrolo[1,2-a]benzimidazole antitumor agents-the design of selective antitumor agents Curr. Med. Chem. 2 1996 900 931
9. E.S. Skibo, S. Gordon, L. Bess, R. Boruah, and J. Heileman Studies of pyrrolo[1,2-a]benzimidazole quinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation J. Med. Chem. 40 1997 1327 1339
10. G.A. Kraus, and N. Selvakumar Synthetic routes to pyrroloiminoquinone alkaloids. A direct synthesis of makaluvamine C J. Org. Chem. 63 1998 9846 9849
11. N.R. Ayyangar, and K.V. Srinivasan Effect of substituents in the formation of diacetanilides Can. J. Chem. 62 1984 1292 1296
12. H. Zimmer, D.C. Lankin, and S.W. Horgan Oxidations with potassium nitrosodisulfonate (Fremy's radical). The Teuber reaction Chem. Rev. 71 1971 229 246
13. D.K. Paull, R.H. Shoemaker, L. Hodes, A. Monks, D.A. Scudiero, L. Rubinstein, J. Plowman, and M.R. Boyd Display and analysis of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm J. Natl. Cancer Inst. 81 1989 1088 1092
14. M.R. Boyd Principles and Practices of Oncology (PPO Updates) 1989 J.B. Lippincott Phildelphia, PA, USA pp 1-12
15. C. Xing, E.B. Skibo, and R.T. Dorr Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure activity relationships for cytotoxicity and antitumor activity J. Med. Chem. 44 2001 3545 3562
16. E.A. Sausville, D. Zaharevitz, R. Gussio, L. Meijer, M. Louarn-Leost, C. Kunick, R. Schultz, T. Lahusen, D. Headlee, S. Stinson, S.G. Arbuck, and A. Senderowicz Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target Pharmacol. Ther. 82 1999 285 292
17. D.T. Ross, U. Scherf, M.B. Eisen, C.M. Perou, C. Rees, P. Spellman, V. Iyer, S.S. Jeffrey, M. Van De Rijn, M. Waltham, A. Pergamenschikov, J.C.E. Lee, D. Lashkari, D. Shalon, T.G. Myers, J.N. Weinstein, D. Botstein, and P.O. Brown Systematic variation in gene expression patterns in human cancer cell lines Nat. Genet. 24 2000 227 235
18. M. Oblak, M. Randic, and T. Solmajer Quantitative structure-activity relationship of flavonoid analogues. 3. Inhibition of p56lck protein tyrosine kinase J. Chem. Inf. Comput. Sci. 40 2000 994 1001
19. I.H. Hall, O.T. Wong, R. Simlot, M.C.I. Miller, and R.A. Izydore Antineoplastic activities and cytotoxicity of 1-acyl and 1,2-diacyl-1,2,4- triazolidine-3,5-diones in murine and human tissue culture cells Anticancer Res. 12 1992 1355 1361
20. D.P. Griswold Consideration of the subcutaneously implanted B16 Melanoma as a screening model foe potential anticancer agents Cancer Chemother. Rep. 3 1972 315 324